Invivyd (Nasdaq: IVVD) has dosed the first participants in LIBERTY, a Phase 3 randomized, double-blind clinical trial evaluating VYD2311, the company's investigational monoclonal antibody (mAb) candidate positioned as a vaccine-alternative for COVID-19 prevention. The trial, which enrolled healthy adults, is assessing three arms: VYD2311 alone, an mRNA COVID-19 vaccine alone, and VYD2311 co-administered with an mRNA COVID-19 vaccine. Topline safety, tolerability, and immunology data are expected in Q3 2026.
VYD2311 is a monoclonal antibody engineered for the prevention — rather than treatment — of COVID-19, targeting individuals who may not mount adequate immune responses to conventional mRNA vaccination or who seek alternative prophylactic options. The LIBERTY trial's co-administration arm is designed to characterize how simultaneous delivery of a passive antibody and an active vaccine affects immunological endpoints, a clinically meaningful question as both modalities target overlapping antigen profiles. The double-blind, placebo-controlled design strengthens the evidentiary weight of any resulting safety and tolerability findings.
The launch of LIBERTY runs concurrently with Invivyd's DECLARATION pivotal trial, with the company anticipating that data from both studies will be reported in tandem. This parallel-track approach is consistent with accelerated regulatory development strategies increasingly common in the post-pandemic biologics pipeline, where sponsors seek to compress timelines between Phase 3 readout and potential regulatory submission. The nutraceutical and functional food sectors have watched the broader immune-support category — estimated to be among the fastest-growing segments in consumer health — closely track clinical developments in adjacent pharmaceutical immune modulation.
For operators and formulators in the functional foods and dietary supplement space, the LIBERTY trial underscores the growing consumer and clinician appetite for evidence-based immune intervention. Immune-support finished formulations — ranging from beta-glucan and elderberry standardized extracts to probiotic blends dosed at clinically validated CFU levels — have benefited from heightened consumer awareness around COVID-era immunity. As pharmaceutical-grade mAb candidates like VYD2311 advance through Phase 3, ingredient suppliers and brand owners in the supplement channel may find renewed pressure to align structure-function claims with robust clinical endpoints rather than general wellness positioning. Categories such as immune-support nutraceuticals and emerging bioactive ingredients are particularly sensitive to this evidentiary shift.
Depending on enrollment pace, Invivyd expects to consolidate LIBERTY and DECLARATION readouts in a single Q3 2026 data package — a timeline that, if met, could inform a regulatory filing before year-end. The New Haven-based company has not disclosed enrollment targets or per-arm sample sizes at this stage.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.